trending Market Intelligence /marketintelligence/en/news-insights/trending/NIAHWbzwmTDak-QniWy1cA2 content esgSubNav
In This List

DBV Technologies prices $125M global offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


DBV Technologies prices $125M global offering

DBV Technologies SA priced a global offering to raise $125 million, just days after it announced the U.S. Food and Drug Administration accepted its application for peanut allergy therapy Viaskin Peanut.

The French company is looking to sell 9,484,066 ordinary shares made up of 7,914,622 stock that will be sold to investors in the U.S., Canada and certain countries outside of Europe at $6.59 apiece, and 1,569,444 for interested buyers in Europe at €12.04 each.

Goldman Sachs, Citigroup, JMP Securities, H.C. Wainwright & Co. and Bryan Garnier & Co. are overseeing the offering. The underwriters can buy up to an additional 1,368,667 shares from the company.

The company expects the offering to close Oct. 11, raising funds for the commercialization of its peanut allergy therapy Viaskin Peanut.